Through education, consensus building and advocacy, the Best Medicines Coalition addresses issues related to pharmaceutical regulatory review, assessment, reimbursement and supply Coalition positions are communicated to policy decision makers and stakeholders in a range of ways including through submissions to formal consultations, representation on advisory bodies, development and distribution of position documents, correspondence, meetings and presentations.
We support reforms which will allow all Canadians to access the medicines they need when needed, equitably and consistently, as outlined in our core positions and principles, and in formal submissions.
CADTH Advisory Panel:
BMC Submission on Potential Pan-Canadian Formulary (February 25, 2022)
National Strategy for Drugs for Rare Diseases:
BMC’s Submission on the National Strategy for Drugs for Rare Diseases — Additional Considerations (August 15, 2022)
Pharmacare Advisory Council:
BMC’s Position Points on Key Recommendations (July 2019)
Joint Discussion Paper:
Better Pharmacare For Patients: Evaluating Policy Options (June 2018) (Français)
We support a strong regulatory framework for pharmaceutical pricing which ensures value and an environment which delivers the best possible care for patients.
PMPRB 2022 Draft Guidelines Consultation (December 5, 2022)
We a support a national regulatory framework which protects Canadian patients, including addressing supply issues like drug shortages which put patients at risk.
Federal Health Mandate: Put patient values, needs and improved outcomes at the centre of health and pharmaceutical policy (November 15, 2021)
We seek pharmaceutical assessment which incorporates patient-driven evidence and perspectives and leads to improved patient care.
Health Technology Assessment in Canada: Improving the System and Ensuring the Patient Voice is Heard (February 2014)